Anonymous
Guest
Anonymous
Guest
http://blogs.wsj.com/moneybeat/2014...n-worth-220share-if-valeant-bid-goes-through/
By ROB COPELAND and MAUREEN FARRELL
Hedge-fund manager John Paulson believes Allergan Inc.AGN +0.88% shares could be worth almost double their current price if Valeant Pharmaceuticals International Inc.VRX.T +2.32% is successful in taking over the Botox maker.
Mr. Paulson’s firm, Paulson & Co., last month revealed it owns about 6 million shares of Allergan, or about 2% of the company, and supports the proposed $53 billion deal. Valeant shares were trading at around $121 Wednesday afternoon.
Mr. Paulson was speaking at CNBC’s Delivering Alpha conference in New York.
Valeant and William Ackman‘s hedge fund, Pershing Square Capital Management LP, have teamed on the takeover bid for Allergan. Mr. Paulson didn’t respond to a direct question from the moderator at the event about whether he had spoken with Mr. Ackman about the proposed deal.
Earlier Wednesday, Mr. Ackman sent a letter to Allergan’s board criticizing its response to the takeover proposal. In the letter, reviewed by The Wall Street Journal, Mr. Ackman said Allergan has violated its fiduciary duty by not negotiating.
By ROB COPELAND and MAUREEN FARRELL
Hedge-fund manager John Paulson believes Allergan Inc.AGN +0.88% shares could be worth almost double their current price if Valeant Pharmaceuticals International Inc.VRX.T +2.32% is successful in taking over the Botox maker.
Mr. Paulson’s firm, Paulson & Co., last month revealed it owns about 6 million shares of Allergan, or about 2% of the company, and supports the proposed $53 billion deal. Valeant shares were trading at around $121 Wednesday afternoon.
Mr. Paulson was speaking at CNBC’s Delivering Alpha conference in New York.
Valeant and William Ackman‘s hedge fund, Pershing Square Capital Management LP, have teamed on the takeover bid for Allergan. Mr. Paulson didn’t respond to a direct question from the moderator at the event about whether he had spoken with Mr. Ackman about the proposed deal.
Earlier Wednesday, Mr. Ackman sent a letter to Allergan’s board criticizing its response to the takeover proposal. In the letter, reviewed by The Wall Street Journal, Mr. Ackman said Allergan has violated its fiduciary duty by not negotiating.